Protalix is developing investigational therapies to address multiple areas of unmet medical need including, Fabry disease, biodefense indications, and autoimmune diseases (including rheumatoid arthritis). More information on these conditions is provided below.
About Fabry Disease
Fabry disease, an inherited condition, has an incidence of about 1 in 40,000 live births. People with Fabry disease do not have enough of an enzyme, alpha-galactosidase A, which breaks down the lipid globotriaosylceramide (GL-3) in the body. As a result, progressive lipid accumulation leads to cell damage throughout the body, causing a wide range of symptoms, including potentially life-threatening episodes such as kidney failure, heart attacks and strokes.
Biodefense refers to therapeutic measures to protect people (both civilians and military personnel) against exposure to potentially dangerous biological agents. These therapeutics can include medicines and vaccinations. Biodefense also includes medical research and preparations to defend against bioterrorist attacks.
About Rheumatoid Arthritis
Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints, as well as systemic inflammation. It can lead to long-term joint damage, resulting in chronic pain, loss of function and disability. RA is a common disease, with a worldwide prevalence of approximately 1-2%. The disease is three times more common in women as in men, afflicts people of all races equally, and can begin at any age, but it most often starts after 40 years of age and before 60 years of age.